Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab in Relapsing Remitting Multiple Sclerosis
NCT02782858Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Apr 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of temelimab in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by GeNeuro. Primary endpoint: Cumulative number of Gd-enhancing T1 lesions in brain MRI. Started Apr 2016; status: completed.
02
Drugs
temelimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02782858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782858.